Patents by Inventor Gregory D. Cuny

Gregory D. Cuny has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150210727
    Abstract: Disclosed are compounds and pharmaceutically acceptable salts thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound selectively inhibits a parasitic IMPDH versus a host IMPDH. Also disclosed are pharmaceutical compositions comprising one or more compounds of the invention. Related methods of treating various parasitic and bacterial infections in mammals are disclosed. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.
    Type: Application
    Filed: August 19, 2013
    Publication date: July 30, 2015
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Lizbeth K. Hedstrom, Gregory D. Cuny, Suresh K. Gorla, Mandapati Kavitha
  • Publication number: 20150157607
    Abstract: This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.
    Type: Application
    Filed: October 10, 2014
    Publication date: June 11, 2015
    Inventors: Albert Edge, Sang-Jun Jeon, Kathleen Seyb, Marcie Glicksman, Lixin Qiao, Gregory D. Cuny
  • Patent number: 9045484
    Abstract: The present invention provides pyridinyl-substituted pyrazolyl pyrimidine small molecule inhibitors of bone morphogenetic protein (BMP) signaling having the structure of formula (I), wherein variables A, B, E, F, X, Y, Z, Ar, L1, R4 and R15 are as defined in the specification. The compounds of the invention are useful in modulating cell growth, differentiation, proliferation, and apoptosis, and thus are useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: June 2, 2015
    Assignees: The Brigham and Women's Hospital, Inc., The General Hospital Corporation
    Inventors: Paul B. Yu, Gregory D. Cuny, Kenneth D. Bloch, Randall T. Peterson, Charles C. Hong
  • Publication number: 20150099781
    Abstract: Described herein are compounds, and pharmaceutically acceptable salts and prodrugs thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound of the invention selectively inhibits a parasitic IMPDH versus a host IMPDH. Further, the invention provides pharmaceutical compositions comprising one or more compounds of the invention. The invention also relates to methods of treating various parasitic and bacterial infections in mammals. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.
    Type: Application
    Filed: December 16, 2014
    Publication date: April 9, 2015
    Inventors: Lizbeth K. Hedstrom, Gregory D. Cuny, Deviprasad R. Gollapalli, Sivapriya Kirubakaran, Sushil K. Maurya, Boris Striepen, Suresh K. Gorla, Corey R. Johnson, Mandapati Kavitha, Jihan Khan
  • Patent number: 8969342
    Abstract: Described herein are compounds, and pharmaceutically acceptable salts and prodrugs thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound of the invention selectively inhibits a parasitic IMPDH versus a host IMPDH. Further, the invention provides pharmaceutical compositions comprising one or more compounds of the invention. The invention also relates to methods of treating various parasitic and bacterial infections in mammals. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: March 3, 2015
    Assignees: Brandeis University, University of Georgia Research Foundation, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Lizbeth K. Hedstrom, Gregory D. Cuny, Deviprasad R. Gollapalli, Boris Striepen, Suresh Kumar Gorla, Mandapati Kavitha
  • Publication number: 20150011603
    Abstract: The invention is directed to compounds according to formula (I): where R1 is L1C(O)OT or L1C(O)OL2C(O)OT; R2 is a substituted or unsubstituted C1-C10 alkyl, C2-C10 alkenyl, or C2-C10 alkynyl, or R1; n is an integer from 0 to 5; each R3 is independently halogen or R2; R4 and R5 are independently H, halogen, CN or CF3; L1 and L2 are each independently a bond, a substituted or unsubstituted C1-C10 alkylene, C2-C10 alkenylene, or C2-C10 alkynylene; and T is H, a substituted or unsubstituted C1-C10 alkyl, C2-C10 alkenyl, or C2-C10 alkynyl, nitrophenol, or cyclopropyl. The invention is also directed to a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier, and to methods for providing anesthesia in mammals by administering such a pharmaceutical composition.
    Type: Application
    Filed: May 19, 2014
    Publication date: January 8, 2015
    Applicants: THE GENERAL HOSPITAL CORPORATION, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Douglas E. RAINES, Joseph F. COTTEN, Stuart A. FORMAN, Keith W. MILLER, Syed S. HUSAIN, Gregory D. CUNY
  • Patent number: 8927545
    Abstract: EphB3 kinase inhibitor compounds, including certain pyrazolo[1,5-a]pyridine and imidazo[1,2-a]pyridine compounds, inhibit EphB3 kinase. The EphB3 kinase inhibitor compounds can have greater potency for the inhibition of EphB3 kinase than general kinase inhibitors. Pharmaceutical compositions, such as neuroprotective agents, comprising the EphB3 kinase inhibitor compounds are also provided. The EphB3 kinase inhibitor compounds and pharmaceutical compositions are useful, for example, to provide neuroprotection and/or repair of neuronal tissue damaged during an ischemic event, such as a stroke.
    Type: Grant
    Filed: March 30, 2010
    Date of Patent: January 6, 2015
    Assignees: Duke University, The Brigham and Women's Hospital, Inc.
    Inventors: Lixin Qiao, Marcie Glicksman, Thomas Gainer, Donald C. Lo, Ross L. Stein, Sungwoon Choi, Gregory D. Cuny
  • Publication number: 20140323489
    Abstract: The present invention relates to heterocyclic compounds (e.g., compounds described by Formula (I)) and pharmaceutically acceptable salts thereof. The invention also features pharmaceutical compositions that include these compounds and their use in therapy for treating conditions in which necroptosis is likely to play a substantial role. The heterocyclic compounds described herein can also achieve improved activity and selectivity towards RIP1 and/or RIP3.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 30, 2014
    Applicants: President and Fellows of Harvard College, University of Houston, Tufts University, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciencess
    Inventors: Junying YUAN, Alexei DEGTEREV, Gregory D. CUNY
  • Patent number: 8859597
    Abstract: This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: October 14, 2014
    Assignees: Massachusetts Eye & Ear Infirmary, Brigham & Women's Hospital, Inc.
    Inventors: Albert Edge, Sang-Jun Jeon, Kathleen Seyb, Marcie Glicksman, Lixin Qiao, Gregory D. Cuny
  • Publication number: 20140303174
    Abstract: Pyridazine derivatives that activate the excitatory amino acid transporter 2 (EAAT2), and methods of use thereof for treating or preventing diseases, disorders, and conditions associated with glutamate excitotoxicity.
    Type: Application
    Filed: August 2, 2012
    Publication date: October 9, 2014
    Applicant: THE BRIGHAM AND WOMEN S HOSPITAL, INC.
    Inventors: Gregory D. Cuny, Marcie Glicksman, Xeuchao Xing, Chien-Liang Glenn Lin
  • Publication number: 20140193906
    Abstract: Disclosed herein are compositions and methods for treatment of spinal muscular atrophy (SMA). In certain embodiments, compounds are provided that increase full-length survival of motor neuron (SMN) protein production by an SMN2 gene.
    Type: Application
    Filed: July 12, 2013
    Publication date: July 10, 2014
    Inventors: Elliot Androphy, Gregory D. Cuny, Jonathan Cherry, Marcie A. Glicksman
  • Patent number: 8765973
    Abstract: The invention is directed to compounds according to formula (I): where R1 is L1C(O)OT or L1C(O)OL2C(O)OT; R2 is a substituted or unsubstituted C1-C10 alkyl, C2-C10 alkenyl, or C2-C10 alkynyl, or R1; n is an integer from 0 to 5; each R3 is independently halogen or R2; R4 and R5 are independently H, halogen, CN or CF3; L1 and L2 are each independently a bond, a substituted or unsubstituted C1-C10 alkylene, C2-C10 alkenylene, or C2-C10 alkynylene; and T is H, a substituted or unsubstituted C1-C10 alkyl, C2-C10 alkenyl, or C2-C10 alkynyl, nitrophenol, or cyclopropyl. The invention is also directed to a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier, and to methods for providing anesthesia in mammals by administering such a pharmaceutical composition.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: July 1, 2014
    Assignee: The General Hospital Corporation
    Inventors: Douglas E. Raines, Joseph F. Cotten, Stuart A. Forman, Keith W. Miller, Syed S. Husain, Gregory D. Cuny
  • Patent number: 8741942
    Abstract: The present invention relates to compounds and pharmaceutical preparations and their use in therapy for preventing or treating trauma, ischemia, stroke and degenerative diseases associated with cell death. Methods and compositions of the invention are particularly useful for treating neurological disorders associated with cellular necrosis.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: June 3, 2014
    Assignees: President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc.
    Inventors: Gregory D. Cuny, Prakash Jagtap, Junying Yuan, Alexei Degterev
  • Publication number: 20140128437
    Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.
    Type: Application
    Filed: January 10, 2014
    Publication date: May 8, 2014
    Applicants: President and Fellows of Harvard College, TRUSTEES OF BOSTON UNIVERSITY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC., Tufts University
    Inventors: Gregory D. Cuny, Xin Teng, Junying Yuan, Alexei Degterrev, John A. Proco, JR.
  • Patent number: 8658689
    Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: February 25, 2014
    Assignees: President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc., Tufts University, Trustees of Boston University
    Inventors: Gregory D. Cuny, Xin Teng, Junying Yuan, Alexei Degterev, John A. Porco, Jr.
  • Publication number: 20140011805
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
    Type: Application
    Filed: July 12, 2013
    Publication date: January 9, 2014
    Inventors: Paul B. Yu, Gregory D. Cuny, Kenneth D. Bloch, Randall T. Peterson, Charles C. Hong
  • Publication number: 20130253005
    Abstract: Provided are small molecule inhibitors of ubiquitin specific protease 1 (USP1) activity and methods for their use in treating and characterizing cancers. The small molecule USP1 inhibitors of the invention are particularly useful in the treatment of cancers that are resistant to DNA cross-linking agents.
    Type: Application
    Filed: April 29, 2011
    Publication date: September 26, 2013
    Applicants: The Brigham and Women's Hospital, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Alan D. D'Andrea, Gregory D. Cuny, Ross L. Stein, Marcie Glicksman, April Case, Jun Xian, David Wilson, Min Huang
  • Publication number: 20130231360
    Abstract: The present disclosure is directed to compounds of Formula (I) which are inhibitors of Haspin kinase and DYRK kinases. The compounds of the present disclosure, and compositions thereof, are useful in the treatment of disease related to Haspin kinase and DYRK kinase expression and/or activity.
    Type: Application
    Filed: April 21, 2011
    Publication date: September 5, 2013
    Applicant: THE BRIGHAM AND WOMEN S HOSPITAL, INC.
    Inventors: Jonathan Higgins, Debasis Patnaik, Natalia Ulyanova, Ross L. Stein, Jun Xian, Marcie Glicksman, Gregory D. Cuny
  • Patent number: 8507501
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: August 13, 2013
    Assignees: The Brigham and Women's Hospital, Inc., The General Hospital Corporation
    Inventors: Paul B. Yu, Gregory D. Cuny, Kenneth D. Bloch, Randall T. Peterson, Charles C. Hong
  • Publication number: 20130158024
    Abstract: The present invention features compounds, pharmaceutical compositions, and methods for treating trauma, ischemia, stroke, degenerative diseases associated with cellular necrosis, and other conditions. Screening assays for identifying compounds useful for treating these conditions are also described.
    Type: Application
    Filed: October 31, 2012
    Publication date: June 20, 2013
    Inventors: Junying Yuan, Alexei Degterev, Junichi Hitomi, Gregory D. Cuny, Prakash Jagtap